Suven [SUVENPHAR] vs Eris Lifesciences [ERIS] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Suven Pharmaceuticals Ltd. wins in 8 metrics, Eris Lifesciences Ltd. wins in 11 metrics, with 0 ties. Eris Lifesciences Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Suven Pharmaceuticals Ltd. | Eris Lifesciences Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 99.01 | 44.25 | Eris Lifesciences Ltd. |
| Price-to-Book Ratio | 13.88 | 6.15 | Eris Lifesciences Ltd. |
| Debt-to-Equity Ratio | 1.95 | 68.19 | Suven Pharmaceuticals Ltd. |
| PEG Ratio | -9.13 | 2.33 | Eris Lifesciences Ltd. |
| EV/EBITDA | 72.65 | 17.91 | Eris Lifesciences Ltd. |
| Profit Margin (TTM) | 26.63% | 14.06% | Suven Pharmaceuticals Ltd. |
| Operating Margin (TTM) | 31.70% | 26.38% | Suven Pharmaceuticals Ltd. |
| EBITDA Margin (TTM) | 31.70% | 26.38% | Suven Pharmaceuticals Ltd. |
| Return on Equity | 14.38% | 10.75% | Suven Pharmaceuticals Ltd. |
| Return on Assets (TTM) | 8.73% | 5.00% | Suven Pharmaceuticals Ltd. |
| Free Cash Flow (TTM) | $1.32B | $9.10B | Eris Lifesciences Ltd. |
| Dividend Yield | N/A | 0.41% | N/A |
| 1-Year Return | 32.02% | -21.75% | Suven Pharmaceuticals Ltd. |
| Price-to-Sales Ratio (TTM) | 39.38 | 6.31 | Eris Lifesciences Ltd. |
| Enterprise Value | $266.01B | $217.40B | Suven Pharmaceuticals Ltd. |
| EV/Revenue Ratio | 25.37 | 7.09 | Eris Lifesciences Ltd. |
| Gross Profit Margin (TTM) | 66.67% | 72.12% | Eris Lifesciences Ltd. |
| Revenue per Share (TTM) | $41 | $225 | Eris Lifesciences Ltd. |
| Earnings per Share (Diluted) | $10.90 | $31.54 | Eris Lifesciences Ltd. |
| Beta (Stock Volatility) | 1.13 | -0.14 | Eris Lifesciences Ltd. |
Suven Pharmaceuticals Ltd. vs Eris Lifesciences Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Suven Pharmaceuticals Ltd. | -1.24% | 6.42% | 7.30% | -9.89% | 2.86% | 2.86% |
| Eris Lifesciences Ltd. | -1.44% | 1.41% | 0.98% | 5.69% | -12.73% | -7.79% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Suven Pharmaceuticals Ltd. | 32.02% | 132.38% | 270.69% | 643.80% | 643.80% | 643.80% |
| Eris Lifesciences Ltd. | -21.75% | 112.96% | 97.43% | 133.52% | 133.52% | 133.52% |
Performance & Financial Health Analysis: Suven Pharmaceuticals Ltd. vs Eris Lifesciences Ltd.
| Metric | SUVENPHAR | ERIS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹412.87B | ₹193.36B |
| Market Cap Category | Large cap | Mid cap |
| 10 Day Avg. Volume | 270,601 | 174,049 |
| 90 Day Avg. Volume | 308,763 | 106,619 |
| Last Close | ₹1,083.35 | ₹1,384.40 |
| 52 Week Range | ₹815.05 - ₹1,360.00 | ₹1,200.00 - ₹1,900.00 |
| % from 52W High | -20.34% | -27.14% |
| All-Time High | ₹1,360.00 (Dec 02, 2024) | ₹1,910.00 (Jun 09, 2025) |
| % from All-Time High | -20.34% | -27.52% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.40% | 0.11% |
| Quarterly Earnings Growth | 0.77% | 0.19% |
| Financial Health | ||
| Profit Margin (TTM) | 0.27% | 0.14% |
| Operating Margin (TTM) | 0.32% | 0.26% |
| Return on Equity (TTM) | 0.14% | 0.11% |
| Debt to Equity (MRQ) | 1.95 | 68.19 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹77.73 | ₹226.84 |
| Cash per Share (MRQ) | ₹25.80 | ₹5.49 |
| Operating Cash Flow (TTM) | ₹2.95B | ₹7.57B |
| Levered Free Cash Flow (TTM) | ₹2.65B | ₹3.52B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.41% |
| Last 12-Month Dividend | ₹0.00 | ₹7.35 |
Valuation & Enterprise Metrics Analysis: Suven Pharmaceuticals Ltd. vs Eris Lifesciences Ltd.
| Metric | SUVENPHAR (Jul 18, 2025) | ERIS (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 99.01 | 44.25 |
| Forward P/E | 57.20 | 27.76 |
| PEG Ratio | -9.13 | 2.33 |
| Price to Sales (TTM) | 39.38 | 6.31 |
| Price to Book (MRQ) | 13.88 | 6.15 |
| Market Capitalization | ||
| Market Capitalization | ₹412.87B | ₹193.36B |
| Enterprise Value | ₹266.01B | ₹217.40B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 25.37 | 7.09 |
| Enterprise to EBITDA | 72.65 | 17.91 |
| Risk & Other Metrics | ||
| Beta | 1.13 | -0.14 |
| Book Value per Share (MRQ) | ₹77.73 | ₹226.84 |
Financial Statements Comparison: Suven Pharmaceuticals Ltd. vs Eris Lifesciences Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | SUVENPHAR (2025) | ERIS (2025) |
|---|---|---|
| Revenue/Sales | 11.98B | 28.79B |
| Cost of Goods Sold | 3.05B | 7.30B |
| COGS % of Revenue | 25.5% | 25.4% |
| Gross Profit | 8.92B | 21.49B |
| Gross Margin | 74.5% | 74.6% |
| Research & Development | N/A | 24.40M |
| Operating Income (EBIT) | 2.98B | 7.03B |
| Operating Margin | 24.9% | 24.4% |
| EBITDA | 4.34B | 10.33B |
| EBITDA Margin | 36.2% | 35.9% |
| Pre-Tax Income | 3.44B | 4.89B |
| Pre-Tax Income % of Revenue | 28.7% | 17.0% |
| Income Tax | 791.50M | 1.14B |
| Income Tax % of Revenue | 6.6% | 4.0% |
| Net Income (Profit) | 2.65B | 3.75B |
| Profit Margin | 22.1% | 13.0% |
Balance Sheet & Liquidity Metrics
| Metric | SUVENPHAR (2025) | ERIS (2025) |
|---|---|---|
| Cash & Equivalents | 854.00M | 2.00B |
| Total Current Assets | 8.89B | 12.23B |
| Total Current Assets % of Revenue | 74.2% | 42.5% |
| Total Current Liabilities | 3.65B | 13.81B |
| Total Current Liabilities % of Revenue | 30.5% | 48.0% |
| Long-Term Debt | 1.76B | 17.82B |
| Long-Term Debt % of Revenue | 14.7% | 61.9% |
| Total Shareholders Equity | 18.41B | 32.72B |
| Retained Earnings | N/A | 27.93B |
| Retained Earnings % of Revenue | 0.0% | 97.0% |
| Property, Plant & Equipment | 9.95B | 2.36B |
Cash Flow Statement Comparison
| Metric | SUVENPHAR (2025) | ERIS (2025) |
|---|---|---|
| Operating Cash Flow | 2.95B | 7.57B |
| Operating Cash Flow % of Revenue | 24.6% | 26.3% |
| Capital Expenditures | -1.56B | -1.55B |
| Free Cash Flow | 1.32B | 9.10B |
| FCF Margin | 11.1% | 31.6% |
| Debt Repayment | -18.50M | -18.34B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SUVENPHAR | ERIS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 254.56M | 138.54M |
| Float Shares | 101.32M | 43.42M |
| % Held by Insiders | 73.19% | 68.05% |
| % Held by Institutions | 14.76% | 21.83% |
| % Held by Public | 12.05% | 10.12% |
Dividend Analysis & Yield Comparison: Suven Pharmaceuticals Ltd. vs Eris Lifesciences Ltd.
| Metric | SUVENPHAR | ERIS |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹7.35 |
| Last 12-Month Dividend Yield | N/A | 0.41% |
| 3-Year Avg Annual Dividend | ₹0.33 | ₹4.90 |
| 3-Year Avg Dividend Yield | 0.22% | 0.82% |
| 3-Year Total Dividends | ₹1.00 | ₹14.70 |
| Ex-Dividend Date | Sep 09, 2022 | Feb 13, 2025 |